Mounjaro®
Starting from £179.99/mo
Start journey Learn moreA three-month supply of Mounjaro covers roughly 12 weekly injections, typically spanning two to three dose steps as your prescriber titrates from the 2.5 mg starter pen upward. That journey looks different for everyone, but the clinical shape of the first three months is well-established. Because Mounjaro is a prescription-only medicine, a prescriber assesses your suitability before any treatment begins — and reviews your case again before each repeat is approved.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen exists for one reason: to let your digestive system get used to a new class of medicine. The 2.5 mg dose activates both the GIP and GLP-1 receptors that Mounjaro targets, but at a level calibrated for adjustment rather than maximum effect. Nausea, loose stools, or a quieter appetite are the most commonly reported experiences in these early weeks, typically mild and settling within days rather than weeks for most people. The NHS tirzepatide medicines page covers what to expect week by week and which symptoms warrant a call to your prescriber. Sticking to smaller portions, eating slowly, and drinking water between meals rather than with food all help your body adapt. One question our prescribers hear most weeks is whether the first month "counts", it does, even if the scales haven't moved dramatically yet. Appetite changes, improved satiety, and early metabolic shifts are already underway.
After four weeks at 2.5 mg, most titration schedules move to 5 mg) but only once a prescriber is satisfied the previous dose was tolerated and that an increase is clinically appropriate for you. This step is where many people notice a more obvious reduction in appetite and, alongside a reduced-calorie diet and regular activity, early meaningful weight change. Side effects may briefly return around a dose increase, usually for a few days. At this point it is worth reviewing your eating patterns with the lifestyle support that should accompany any weight-management medicine; the treatment overview at nume explains how lifestyle guidance fits alongside clinical care. For people who find 5 mg harder to tolerate, staying at that level for longer before any further increase is a legitimate and common clinical decision, titration speed is personal, not a race. Progress at this stage varies considerably, and that variation is normal.
By the end of a three-month course many people are at 5 mg or 7.5 mg, depending on their response and tolerability. The three-month mark is a natural clinical checkpoint: your prescriber can assess how much weight change has occurred, how well the dose has been tolerated, and whether continuing or adjusting is the right next step. NICE's appraisal of tirzepatide (TA1026) sets out the expectation that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed, so month three is a useful halfway audit. It is also when the practical rhythm of once-weekly injections tends to feel genuinely routine. If you are sourcing treatment privately, a repeat is not automatic: a clinical review comes first. That is not an obstacle, it is the point. It keeps the treatment safe. For a closer look at what the evidence says about outcomes at this stage, the three months on Mounjaro page covers the clinical data in detail.
Three months means three separate pen packs, each requiring a prescription. Private pricing for Mounjaro has shifted since Eli Lilly revised its UK list price in September 2025; for context on how market prices have moved, the Eli Lilly Mounjaro price increase page explains what changed and why. When budgeting across three months, bear in mind that legitimate private treatment includes the cost of clinical assessments, not just the medicine itself. Any provider quoting a bare pen price with consultation fees charged separately will cost more than the headline figure suggests. The right question is not which listing is cheapest; if you want a broader picture of how Mounjaro supply in the UK works across different providers, that page sets out what to look for and why clinical oversight matters. If you are curious how the three-month picture compares with longer treatment, the six-month Mounjaro page picks up where this one leaves off. Full information on eligibility and how our clinical team works is available on the Mounjaro treatment page. Those who want to plan ahead financially may find it useful to review what a three-month Mounjaro supply typically involves in terms of cost and clinical requirements before starting a consultation. When you feel ready to take the next step, starting a free consultation is the natural place to begin.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.